Lysosomal Therapeutics Inc. (LTI) is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Our strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a unique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease and other synucleinopathies.
Neurons, Lysosomes and Disease
Proteins accumulate due to errors in lysosome function, resulting in the damage of neurons. Damaged neurons degenerate and die causing a loss in cognitive, sensory and motor function in common diseases such as Parkinson's and rare diseases such as Gaucher's. LTI is leveraging its world-class knowledge of lysosomal biology and drug development to deliver innovative agents for neurodegenerative disease.
Lysosomal Therapeutics Inc.
Delivering cures for neurodegenerative diseases.